{"id":46737,"date":"2022-07-29T15:01:54","date_gmt":"2022-07-29T13:01:54","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/fresenius-kabi-announces-u-s-availability-of-cancer-therapeutic-thiotepa\/"},"modified":"2022-07-29T15:01:54","modified_gmt":"2022-07-29T13:01:54","slug":"fresenius-kabi-announces-u-s-availability-of-cancer-therapeutic-thiotepa","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/fresenius-kabi-announces-u-s-availability-of-cancer-therapeutic-thiotepa\/","title":{"rendered":"Fresenius Kabi Announces U.S. Availability of Cancer Therapeutic Thiotepa"},"content":{"rendered":"<div>\n<p class=\"bwalignc\">\n<b>Expanding access to affordable oncology medicines<\/b>\n<\/p>\n<p>LAKE ZURICH, Ill.&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/hashtag\/FreseniusKabi?src=hash\" target=\"_blank\" rel=\"noopener\">#FreseniusKabi<\/a>&#8211;Fresenius Kabi announced today it has introduced Thiotepa for Injection, USP, in the United States. Thiotepa, a generic equivalent to Tepadina<sup>\u00ae<\/sup>, is the newest addition to the company\u2019s injectable oncology portfolio \u2013 the most comprehensive in the industry.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220729005063\/en\/1528773\/5\/Thiotepa_FK.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220729005063\/en\/1528773\/21\/Thiotepa_FK.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20220729005063\/en\/341705\/5\/Logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220729005063\/en\/341705\/21\/Logo.jpg\"><\/a><\/p>\n<p>\nFresenius Kabi Thiotepa for Injection, USP is available immediately in 100 mg single-dose vials. It has multiple indications, including for the treatment of patients with adenocarcinoma of the breast or ovary.\n<\/p>\n<p>\n\u201cWe are pleased to add Thiotepa for Injection, USP to our portfolio of generic oncology medicines,\u201d said John Ducker, president and CEO of Fresenius Kabi USA. \u201cAs a company whose purpose is \u2018caring for life,\u2019 we remain committed to supporting patients and their care teams by expanding access to affordable cancer treatment options.\u201d\n<\/p>\n<p>\n<b>INDICATIONS AND USAGE<\/b>\n<\/p>\n<p>\nThiotepa for injection is an alkylating drug indicated:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nFor treatment of adenocarcinoma of the breast or ovary.\n<\/li>\n<li>\nFor controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities.\n<\/li>\n<li>\nFor treatment of superficial papillary carcinoma of the urinary bladder.\n<\/li>\n<\/ul>\n<p>\n<b>IMPORTANT SAFETY INFORMATION<\/b>\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>WARNING: SEVERE MYELOSUPPRESSION, CARCINOGENICITY<\/p>\n<p><\/b>\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b><i>See full prescribing information for complete boxed warning<\/p>\n<p><\/i><\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<b>May cause severe marrow suppression or ablation with resulting infection or bleeding. Monitor hematologic laboratory parameters.<\/b>\n<\/li>\n<li>\n<b>Potentially carcinogenic in humans.<\/b>\n<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n<\/table>\n<p>\nThiotepa for Injection is contraindicated in patients with a hypersensitivity to the active substance and with concomitant use with live or attenuated vaccines.\n<\/p>\n<p>\nCutaneous toxicity: Cleanse skin at least twice daily through 48 hours after the last dose of thiotepa.\n<\/p>\n<p>\nEmbryo-Fetal toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to avoid pregnancy.\n<\/p>\n<p>\nThe most common adverse reactions (incidence greater than 10%) were neutropenia, anemia, thrombocytopenia, elevated alanine aminotransferase, elevated aspartate aminotransferase, elevated bilirubin, mucositis, cytomegalovirus infection, hemorrhage, diarrhea, hematuria and rash.\n<\/p>\n<p>\n<b>To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800\u2010551\u20107176, option 5, or FDA at 1\u2010800\u2010FDA\u20101088 or <\/b><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fda.gov%2Fsafety%2Fmedwatch-fda-safety-information-and-adverse-event-reporting-program&amp;esheet=52795377&amp;newsitemid=20220729005063&amp;lan=en-US&amp;anchor=www.fda.gov%2Fmedwatch.com&amp;index=1&amp;md5=a309f68b1d282516bc8614886732f6f2\" rel=\"nofollow noopener\" shape=\"rect\"><b>www.fda.gov\/medwatch.com<\/b><\/a><b>.<\/b>\n<\/p>\n<p>\nLactation: Breastfeeding is not recommended.\n<\/p>\n<p>\nModerate or severe renal impairment: Monitor patients more frequently for toxicity.\n<\/p>\n<p>\nModerate or severe hepatic impairment: Monitor patients more frequently for toxicity.\n<\/p>\n<p>\n<b>This Important Safety Information does not include all the information needed to use Thiotepa for Injection safely and effectively. Please see full prescribing information for Thiotepa for Injection at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fresenius-kabi.com%2Fus&amp;esheet=52795377&amp;newsitemid=20220729005063&amp;lan=en-US&amp;anchor=www.fresenius-kabi.com%2Fus&amp;index=2&amp;md5=946c2a4bdac4e2a2936f867f81e0bf03\" rel=\"nofollow noopener\" shape=\"rect\">www.fresenius-kabi.com\/us<\/a>.<\/b>\n<\/p>\n<p>\n<b>About Fresenius Kabi<\/b>\n<\/p>\n<p>\nFresenius Kabi (<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fresenius-kabi.com%2Fus&amp;esheet=52795377&amp;newsitemid=20220729005063&amp;lan=en-US&amp;anchor=www.fresenius-kabi.com%2Fus&amp;index=3&amp;md5=937fd586eb63e366d24f51f08a1db9b7\" rel=\"nofollow noopener\" shape=\"rect\">www.fresenius-kabi.com\/us<\/a>) is a global health care company that specializes in medicines and technologies for infusion, transfusion, and clinical nutrition. The company\u2019s products and services are used to help care for critically and chronically ill patients. The company\u2019s U.S. headquarters is in Lake Zurich, Illinois. The company\u2019s global headquarters is in Bad Homburg, Germany. To learn about U.S. career opportunities at Fresenius Kabi, visit us at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fresenius-kabi.com%2Fus%2Fjoin-us&amp;esheet=52795377&amp;newsitemid=20220729005063&amp;lan=en-US&amp;anchor=www.fresenius-kabi.com%2Fus%2Fjoin-us&amp;index=4&amp;md5=c516dac7253297acad58a02680151ad4\" rel=\"nofollow noopener\" shape=\"rect\">www.fresenius-kabi.com\/us\/join-us<\/a> and follow us on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Ffresenius-kabi-usa%2Flife%2F1e773c8e-64e5-4737-b717-36979fd7e2a9%2F%3FviewAsMember%3Dtrue&amp;esheet=52795377&amp;newsitemid=20220729005063&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=5&amp;md5=e6f3f002051199533fced386f7f1a7b3\" rel=\"nofollow noopener\" shape=\"rect\">LinkedIn<\/a>.\n<\/p>\n<p>\n*Tepadina<sup>\u00ae<\/sup> is a registered trademark of Amneal\/Adienne.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Media contact<\/b><br \/>Joanie Clougherty (614) 717-5741<br \/>\n<br \/><a target=\"_blank\" href=\"ma&#105;&#108;&#x74;&#x6f;&#x3a;&#x6a;oa&#110;&#46;&#x63;&#x6c;&#x6f;&#x75;gh&#101;&#114;&#116;&#x79;&#x40;&#x66;&#x72;es&#101;&#110;&#x69;&#x75;&#x73;&#x2d;ka&#98;&#105;&#x2e;&#x63;&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#106;&#x6f;a&#110;&#x2e;c&#108;&#x6f;u&#103;&#x68;e&#114;&#x74;&#121;&#x40;&#x66;&#114;&#x65;&#x73;&#101;&#x6e;i&#117;&#x73;-&#107;&#x61;b&#105;&#x2e;c&#111;&#x6d;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Expanding access to affordable oncology medicines LAKE ZURICH, Ill.&#8211;(BUSINESS WIRE)&#8211;#FreseniusKabi&#8211;Fresenius Kabi announced today it has introduced Thiotepa for Injection, USP, in the United States. Thiotepa, a generic equivalent to Tepadina\u00ae, is the newest addition to the company\u2019s injectable oncology portfolio \u2013 the most comprehensive in the industry. Fresenius Kabi Thiotepa for Injection, USP is available &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/fresenius-kabi-announces-u-s-availability-of-cancer-therapeutic-thiotepa\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46737","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Fresenius Kabi Announces U.S. Availability of Cancer Therapeutic Thiotepa - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/fresenius-kabi-announces-u-s-availability-of-cancer-therapeutic-thiotepa\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fresenius Kabi Announces U.S. Availability of Cancer Therapeutic Thiotepa - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Expanding access to affordable oncology medicines LAKE ZURICH, Ill.&#8211;(BUSINESS WIRE)&#8211;#FreseniusKabi&#8211;Fresenius Kabi announced today it has introduced Thiotepa for Injection, USP, in the United States. Thiotepa, a generic equivalent to Tepadina\u00ae, is the newest addition to the company\u2019s injectable oncology portfolio \u2013 the most comprehensive in the industry. Fresenius Kabi Thiotepa for Injection, USP is available ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/fresenius-kabi-announces-u-s-availability-of-cancer-therapeutic-thiotepa\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-29T13:01:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220729005063\/en\/1528773\/21\/Thiotepa_FK.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fresenius-kabi-announces-u-s-availability-of-cancer-therapeutic-thiotepa\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fresenius-kabi-announces-u-s-availability-of-cancer-therapeutic-thiotepa\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Fresenius Kabi Announces U.S. Availability of Cancer Therapeutic Thiotepa\",\"datePublished\":\"2022-07-29T13:01:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fresenius-kabi-announces-u-s-availability-of-cancer-therapeutic-thiotepa\\\/\"},\"wordCount\":502,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fresenius-kabi-announces-u-s-availability-of-cancer-therapeutic-thiotepa\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220729005063\\\/en\\\/1528773\\\/21\\\/Thiotepa_FK.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fresenius-kabi-announces-u-s-availability-of-cancer-therapeutic-thiotepa\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fresenius-kabi-announces-u-s-availability-of-cancer-therapeutic-thiotepa\\\/\",\"name\":\"Fresenius Kabi Announces U.S. Availability of Cancer Therapeutic Thiotepa - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fresenius-kabi-announces-u-s-availability-of-cancer-therapeutic-thiotepa\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fresenius-kabi-announces-u-s-availability-of-cancer-therapeutic-thiotepa\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220729005063\\\/en\\\/1528773\\\/21\\\/Thiotepa_FK.jpg\",\"datePublished\":\"2022-07-29T13:01:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fresenius-kabi-announces-u-s-availability-of-cancer-therapeutic-thiotepa\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fresenius-kabi-announces-u-s-availability-of-cancer-therapeutic-thiotepa\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fresenius-kabi-announces-u-s-availability-of-cancer-therapeutic-thiotepa\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220729005063\\\/en\\\/1528773\\\/21\\\/Thiotepa_FK.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220729005063\\\/en\\\/1528773\\\/21\\\/Thiotepa_FK.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fresenius-kabi-announces-u-s-availability-of-cancer-therapeutic-thiotepa\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fresenius Kabi Announces U.S. Availability of Cancer Therapeutic Thiotepa\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Fresenius Kabi Announces U.S. Availability of Cancer Therapeutic Thiotepa - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/fresenius-kabi-announces-u-s-availability-of-cancer-therapeutic-thiotepa\/","og_locale":"en_US","og_type":"article","og_title":"Fresenius Kabi Announces U.S. Availability of Cancer Therapeutic Thiotepa - Pharma Trend","og_description":"Expanding access to affordable oncology medicines LAKE ZURICH, Ill.&#8211;(BUSINESS WIRE)&#8211;#FreseniusKabi&#8211;Fresenius Kabi announced today it has introduced Thiotepa for Injection, USP, in the United States. Thiotepa, a generic equivalent to Tepadina\u00ae, is the newest addition to the company\u2019s injectable oncology portfolio \u2013 the most comprehensive in the industry. Fresenius Kabi Thiotepa for Injection, USP is available ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/fresenius-kabi-announces-u-s-availability-of-cancer-therapeutic-thiotepa\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-29T13:01:54+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220729005063\/en\/1528773\/21\/Thiotepa_FK.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/fresenius-kabi-announces-u-s-availability-of-cancer-therapeutic-thiotepa\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/fresenius-kabi-announces-u-s-availability-of-cancer-therapeutic-thiotepa\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Fresenius Kabi Announces U.S. Availability of Cancer Therapeutic Thiotepa","datePublished":"2022-07-29T13:01:54+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/fresenius-kabi-announces-u-s-availability-of-cancer-therapeutic-thiotepa\/"},"wordCount":502,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/fresenius-kabi-announces-u-s-availability-of-cancer-therapeutic-thiotepa\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220729005063\/en\/1528773\/21\/Thiotepa_FK.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/fresenius-kabi-announces-u-s-availability-of-cancer-therapeutic-thiotepa\/","url":"https:\/\/pharma-trend.com\/en\/fresenius-kabi-announces-u-s-availability-of-cancer-therapeutic-thiotepa\/","name":"Fresenius Kabi Announces U.S. Availability of Cancer Therapeutic Thiotepa - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/fresenius-kabi-announces-u-s-availability-of-cancer-therapeutic-thiotepa\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/fresenius-kabi-announces-u-s-availability-of-cancer-therapeutic-thiotepa\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220729005063\/en\/1528773\/21\/Thiotepa_FK.jpg","datePublished":"2022-07-29T13:01:54+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/fresenius-kabi-announces-u-s-availability-of-cancer-therapeutic-thiotepa\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/fresenius-kabi-announces-u-s-availability-of-cancer-therapeutic-thiotepa\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/fresenius-kabi-announces-u-s-availability-of-cancer-therapeutic-thiotepa\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220729005063\/en\/1528773\/21\/Thiotepa_FK.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220729005063\/en\/1528773\/21\/Thiotepa_FK.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/fresenius-kabi-announces-u-s-availability-of-cancer-therapeutic-thiotepa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Fresenius Kabi Announces U.S. Availability of Cancer Therapeutic Thiotepa"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46737","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46737"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46737\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46737"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46737"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46737"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}